Wedbush raised its price target for Beam from $28 to $30 and kept its Outperform rating. That is favorable for Beam, but the story gives no new company results to confirm the analyst's view.
That points to a more favorable view of Beam's clinical and financial progress. The article gives no new company results to confirm that progress, so the positive read rests on Wedbush's judgment.
Follow Beam Therapeutics (BEAM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BEAM